Skip to main content
Equibles
XENE logo

XENE · Xenon Pharmaceuticals Inc. · Metrics

Track XENE — free

Use XENE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XENE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$40.48 -0.52 (-1.26%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$3.98B
Shares
98.28M
Volume · Nov 13 607.68K Avg daily vol (3M) 1.62M

XENE metrics

77 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$40.48
Market cap
$3.98B

Price action

23 metrics
Price change (1W)
+3.3%
Price change (30D)
+17.9%
Price change (3M)
-35.1%
Price change (6M)
-25.6%
Price change (YTD)
-9.7%
Price change (1Y)
+1.1%
Trailing year
Price change (5Y)
+28.7%
52-week high
$70.96
52-week low
$33.49
Change from 52-week high
-43.0%
Change from 52-week low
+20.9%
Annualized volatility
68.1%
Annualized volatility (3M)
71.1%
Implied volatility (30D)
58.1%
IV rank (1Y)
10.9
IV percentile (1Y)
69.7
Beta
0.8
RSI (14D)
54.9
Price vs SMA 50
-1.6%
Price vs SMA 200
-22.6%
Avg volume (3M)
1.62M
Relative volume
0.4
Average dollar volume
$67.13M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
98.28M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.5
reciprocal yield 28.8%
FCF yield
-9.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-09

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$465.32M
Net income (TTM)
−$428.73M
Trailing 12 months
Diluted EPS (TTM)
$-4.70
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5.10
EBITDA per diluted share (TTM)
$-5.07
Net income per diluted share (TTM)
$-4.70
Operating cash flow per diluted share (TTM)
$-3.90
Free cash flow per diluted share (TTM)
$-3.91
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$4.06
Stock compensation per diluted share (TTM)
$0.70
Book value per share
$7.27

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.9%
Year over year · more shares
Revenue CAGR (3Y)
-7.4%
Revenue CAGR (5Y)
-25.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-37.4%
Return on assets
-35.7%
Debt / equity
0.0
Current ratio
21.2
EBITDA (TTM)
−$463.00M
Free cash flow (TTM)
−$357.11M
Quick ratio
21.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$950.80M
Latest balance sheet
Cash & equivalents
$82.56M
Total assets
$1.20B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$356.10M
Capital expenditures (TTM)
$1.01M
R&D (TTM)
$371.08M
SG&A (TTM)
—
Stock compensation (TTM)
$64.29M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
316
13F filer change QoQ
+24
Institutional ownership
104.0%
Conviction holders (share of 13F filers)
3.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-2.6%
Holder tenure
14.9
Price vs estimated holder cost
+38.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.4%

Short interest

3 metrics
Short interest
7.5%
Latest settlement · 6.4 days to cover
Days to cover
6.4d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.26M
Insider-sentiment score
90 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1582313 CUSIP 98420N105 13F (30d) 230 filings 192 filers Visit website Investor relations